Category: Zacks Small Cap Research

1 2 3 26 10 / 255 POSTS
By Steven Ralston, CFATSX:WML.VREAD THE FULL WML.V RESEARCH REPORTExecutive Summary of Recent Events• Wealth Minerals (TSX:WML.V) is junior mining company pursuing a strategy of accumulating early stage exploration lithium projects within the Lithium ...
By Lisa ThompsonNYSE:DSSREAD THE FULL DSS RESEARCH REPORTDocument Security Systems (NYSE:DSS) is a decades old company with expertise in security printing, but with revenues that have been flat for the past few years. Sales are primarily from printin ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTBusiness UpdatePositive Interim Analysis of SGX301 Phase 3 Clinical TrialOn October 15, 2018, Soligenix, Inc. (NASDAQ:SNGX) announced a positive recommendation from the independent Data ...
NYSE:CVMNearing the end of its long running Phase III trial for squamous cell carcinoma of the head and neck (SCCHN), CEL-SCI (NYSE:CVM) has experienced several recent catalysts that have returned attention and interest to their novel immuno-oncology ...
By John Vandermosten, CFATSE:PMN.TO | OTC:ARFXFOn Thursday, ProMIS (TSE:PMN.TO) (OTC:ARFXF) announced another milestone with the identification of several potential monoclonal antibody (mAb) candidates that target toxic oligomers for α-synuclein, whi ...
By Steven Ralston, CFAOTCQX:GRWGREAD THE FULL GRWG RESEARCH REPORTGrowGeneration (OTCQX:GRWG) owns and operates specialty retail hydroponic and organic gardening stores that target the rapidly expanding licensed cannabis cultivators in key markets th ...
By John Vandermosten, CFAOTCQX:DYAIREAD THE FULL DYAI RESEARCH REPORTWe recently initiated on Dyadic International, Inc. (OTCQX:DYAI) with a $4.50 price target and a thesis that recognizes the high costs of biologics production and the opportunity fo ...
By John Vandermosten, CFAOTCQX:DYAIREAD THE FULL DYAI RESEARCH REPORTINITIATING COVERAGEWe are initiating coverage of Dyadic International Inc. (OTCQX:DYAI) with a $4.50 price target based on our estimates for commercialization of the company’s propr ...
By John Vandermosten, CFANASDAQ:RXIIREAD THE FULL RXII RESEARCH REPORTOn October 3rd, 2018 RXi Pharmaceuticals Corp. (NASDAQ:RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17 ...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateMotif Bio Plc (NASDAQ:MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s le ...
1 2 3 26 10 / 255 POSTS